References
- Peiris JS, Yu WC, Leung CW et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet363, 617–619 (2004).
- Tran TH, Nguyen TL, Nguyen TD et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N. Engl. J. Med.350, 1179–1188 (2004).
- Grose C, Chokephaibulkit K. Avian influenza virus infection of children in Vietnam and Thailand. Pediatr. Infect. Dis. J.23, 793–794 (2004).
- Morris SK. H5N1 avian influenza, Kampot Province, Cambodia. Emerg. Infect. Dis.12, 170–171 (2006).
- Butler D. Family tragedy spotlights flu mutations. Nature442, 114–115 (2006).
- Ungchusak K, Auewarakul P, Dowell SF et al. Probable person-to-person transmission of avian influenza A (H5N1). N. Engl. J. Med.352, 333–340 (2005).
- Hien TT, de Jong M, Farrar J. Avian influenza – a challenge to global health care structures. N. Engl. J. Med.351, 2363–2365 (2004).
- Le QM, Kiso M, Someya K et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature437, 1108 (2005).
- Uiprasertkul M, Puthavathana P, Sangsiriwut K et al. Influenza A H5N1 replication sites in humans. Emerg. Infect. Dis.11, 1036–1041 (2005).
- Renger KB, Small PA Jr. Passive immunization: systemic and mucosal. In: Handbook of Mucosal Immunology. Ogra PL, McGhee JR, Mestecky J, Strober W, Bienenstock J (Eds). Academic Press, CA, USA ,347–356 (1994).
- Chen Z, Sahashi Y, Matsuo K et al. Comparison of the ability of viral protein-expressing plasmid DNAs to protect against influenza. Vaccine16, 1544–1549 (1998).
- Chen Z, Kadowaki S, Hagiwara Y et al. Protection against influenza B virus infection by immunization with DNA vaccines. Vaccine19, 1446–1455 (2001).
- O’Neill LA. Immunology. After the toll rush. Science303, 1481–1482 (2004).
- Guillot L, Le Goffic R, Bloch S et al. Involvement of Toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J. Biol. Chem.280, 5571–5580 (2005).
- Kato H, Takeuchi O, Sato S et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature441, 101–105 (2006).
- Leikina E, Delanoe-Ayari H, Melikov K et al. Carbohydrate-binding molecules inhibit viral fusion and entry by crosslinking membrane glycoproteins. Nat. Immunol.6, 995–1001 (2005).
- Asanuma H, Thompson AH, Iwasaki T et al. Isolation and characterization of mouse nasal-associated lymphoid tissue. J. Immunol. Methods202, 123–131 (1997).
- Brandtzaeg P. Overview of the mucosal immune system. Curr. Top. Microbiol. Immunol.146, 13–25 (1989).
- Brandtzaeg P, Baekkevold ES, Farstad IN et al. Regional specialization in the mucosal immune system: what happens in the microcompartments? Immunol. Today20, 141–151 (1999).
- Kuper CF, Koornstra PJ, Hameleers DM et al. The role of nasopharyngeal lymphoid tissue. Immunol. Today13, 219–224 (1992).
- McGhee JR, Mestecky J, Dertzbaugh MT, Eldridge JH, Hirasawa M, Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine10, 75–88 (1992).
- Couch RB, Kasel JA. Immunity to influenza in man. Annu. Rev. Microbiol.37, 529–549 (1983).
- Hoskins TW, Davies JR, Smith AJ, Allchin A, Miller CL, Pollock TM. Influenza at Christ’s hospital: March, 1974. Lancet1, 105–108 (1976).
- Hoskins TW, Davies JR, Smith AJ, Miller CL, Allchin A. Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ’s hospital. Lancet1, 33–35 (1979).
- Murphy BR, Clements ML. The systemic and mucosal immune response of humans to influenza A virus. Curr. Top. Microbiol. Immunol.146, 107–116 (1989).
- Sangster MY, Riberdy JM, Gonzalez M, Topham DJ, Baumgarth N, Doherty PC. An early CD4+ T cell-dependent immunoglobulin A response to influenza infection in the absence of key cognate T–B interactions. J. Exp. Med.198, 1011–1021 (2003).
- Ghendon Y. Cold-adapted, live influenza vaccines developed in Russia. In: Textbook of Influenza. Nicholson KG, Webster RG, Hay AJ (Eds). Blackwell Science, Oxford, UK, 391–399 (1998).
- Keitel WA, Piedra PA. Live cold adapted, reassortant influenza vaccine. In: Textbook of Influenza. Nicholson KG, Webster RG, Hay AJ (Eds). Blackwell Science, Oxford, UK, 373–390 (1998).
- Maassab HF. Adaptation and growth characteristics of influenza virus at 25 degrees C. Nature213, 612–614 (1967).
- Murphy BR. Mucosal immunity to viruses. In: Handbook of Mucosal Immunology. Ogra LL, Lamm ME, McGhee JR, Mestecky J, Strober W, Bienenstock J (Eds). Academic Press, CA, USA, 333–339 (1994).
- Gluck R, Mischler R, Finkel B, Que JU, Scarpa B, Cryz SJ Jr. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet344, 160–163 (1994).
- Gluck R, Mischler R, Finkel B. Immunogenicity of new virosome influenza vaccine in elderly people. In: Textbook of Influenza. Nicholson KG, Webster RG, Hay AJ (Eds). Blackwell Science, Oxford, UK, 74–79 (1998).
- Squarcione S, Sgricia S, Biasio LR, Perinetti E. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine21, 1268–1274 (2003).
- Stephenson I, Bugarini R, Nicholson KG et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J. Infect. Dis.191, 1210–1215 (2005).
- Del Giudice G, Hilbert AK, Bugarini R et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine24, 3063–3065 (2006).
- Hehme N, Engelmann H, Kuenzel W, Neumeier E, Saenger R. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res.103, 163–171 (2004).
- Greenbaum E, Engelhard D, Levy R, Schlezinger M, Morag A, Zakay-Rones Z. Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine. Vaccine22, 2566–2577 (2004).
- Greenbaum E, Furst A, Kiderman A et al. Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine. J. Med. Virol.65, 178–184 (2001).
- Kuno-Sakai H, Kimura M, Ohta K, Shimojima R, Oh Y, Fukumi H. Developments in mucosal influenza virus vaccines. Vaccine12, 1303–1310 (1994).
- Muszkat M, Greenbaum E, Ben-Yehuda A et al. Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccine. Vaccine21, 1180–1186 (2003).
- Muszkat M, Yehuda AB, Schein MH et al. Local and systemic immune response in community-dwelling elderly after intranasal or intramuscular immunization with inactivated influenza vaccine. J. Med. Virol.61, 100–106 (2000).
- Takada A, Kuboki N, Okazaki K et al. A virulent avian influenza virus as a vaccine strain against a potential human pandemic. J. Virol.73, 8303–8307 (1999).
- Diebold SS, Kaisho T, Hemmi H, Akira S, Reise Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science303, 1529–1531 (2004).
- Lund JM, Alexopoulou L, Sato A et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl Acad. Sci. USA101, 5598–5603 (2004).
- Ichinohe T, Watanabe I, Ito S et al. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J. Virol.79, 2910–2919 (2005).
- Jacobs BL, Langland JO. When two strands are better than one: the mediators and modulators of the cellular responses to double-stranded RNA. Virology219, 339–349 (1996).
- Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature413, 732–738 (2001).
- Le Bon A, Schiavoni G, D’Agostino G, Gresser I, Belardelli F, Tough DF. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity14, 461–470 (2001).
- Tamura S, Samegai Y, Kurata H, Nagamine T, Aizawa C, Kurata T Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit. Vaccine6, 409–413 (1988).
- Tamura SI, Asanuma H, Ito Y et al. Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine. Eur. J. Immunol.22, 477–481 (1992).
- Tamura S, Yamanaka A, Shimohara M et al. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine. Vaccine12, 419–426 (1994).
- Tamura S, Ito Y, Asanuma H et al. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J. Immunol.149, 981–988 (1992).
- Kris RM, Asofsky R, Evans CB, Small PA Jr. Protection and recovery in influenza virus-infected mice immunosuppressed with anti-IgM. J. Immunol.134, 1230–1235 (1985).
- Nedrud JG, Liang XP, Hague N, Lamm ME. Combined oral/nasal immunization protects mice from Sendai virus infection. J. Immunol.139, 3484–3492 (1987).
- Ramphal R, Cogliano RC, Shands JW Jr, Small PA Jr. Serum antibody prevents lethal murine influenza pneumonitis but not tracheitis. Infect. Immun.25, 992–997 (1979).
- Couch RB. Nasal vaccination, Escherichia coli enterotoxin, and Bell’s palsy. N. Engl. J. Med.350, 860–861 (2004).
- Hagiwara Y, Komase K, Chen Z et al. Mutants of cholera toxin as an effective and safe adjuvant for nasal influenza vaccine. Vaccine17, 2918–2926 (1999).
- Watanabe I, Ross TM, Tamura S et al. Protection against influenza virus infection by intranasal administration of C3d-fused hemagglutinin. Vaccine21, 4532–4538 (2003).
- Hasegawa H, Ichinohe T, Strong P et al. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant. J. Med. Virol.75, 130–136 (2005).
- Strong P, Clark H, Reid K. Intranasal application of chitin microparticles down-regulates symptoms of allergic hypersensitivity to Dermatophagoides pteronyssinus and Aspergillus fumigatus in murine models of allergy. Clin. Exp. Allergy32, 1794–1800 (2002).
- Schaffner A, Douglas H, Braude A. Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus. Observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes. J. Clin. Invest.69, 617–631 (1982).
- Bacon A, Makin J, Sizer PJ et al. Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect. Immun.68, 5764–5770 (2000).
- Ichinohe T, Watanabe I, Tao E et al. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant. J. Med. Virol.78, 954–963 (2006).
- Chen D, Endres RL, Erickson CA et al. Epidermal immunization by a needle-free powder delivery technology: immunogenicity of influenza vaccine and protection in mice. Nat. Med.6, 1187–1190 (2000).
- Chen D, Periwal SB, Larrivee K et al. Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization. J. Virol.75, 7956–7965 (2001).
- Ulmer JB, Donnelly JJ, Parker SE et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science259, 1745–1749 (1993).
- Mitchell JA, Green TD, Bright RA, Ross TM. Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins. Vaccine21, 902–914 (2003).
- Suguitan AL Jr, McAuliffe J, Mills KL et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med.3(9), e360 (2006).
- Hoelscher MA, Garg S, Bangari DS et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet367, 475–481 (2006).
- Marshall E. Gene therapy death prompts review of adenovirus vector. Science286, 2244–2245 (1999).
- Asahi-Ozaki Y, Itamura S, Ichinohe T et al. Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection. Microbes Infect.8(12–13), 2706–2714 (2006).
- Yoshino N, Lu FX, Fujihashi K et al. A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates. J. Immunol.173, 6850–6857 (2004).
- Davenport FM, Hennessy AV, Brandon FM, Webster RG, Barrett CD Jr, Lease GO. Comparisons of serologic and febrile responses in humans to vaccination with influenza a viruses or their hemagglutinins. J. Lab. Clin. Med.63, 5–13 (1964).
- Bachmayer H. Selective solubilization of hemagglutinin and neuraminidase from influenza viruses. Intervirology5, 260–272 (1975).
- Brady MI, Furminger IG. A surface antigen influenza vaccine. 1. Purification of haemagglutinin and neuraminidase proteins. J. Hyg. (Lond.)77, 161–172 (1976).
- Brady MI, Furminger IG. A surface antigen influenza vaccine. 2. Pyrogenicity and antigenicity. J. Hyg. (Lond.)77, 173–180 (1976).
- Greenbaum E, Furst A, Kiderman A et al. Mucosal [SIgA] and serum [IgG] immunologic responses in the community after a single intranasal immunization with a new inactivated trivalent influenza vaccine. Vaccine20, 1232–1239 (2002).
- Durrer P, Gluck U, Spyr C et al. Mucosal antibody response induced with a nasal virosome-based influenza vaccine. Vaccine21, 4328–4334 (2003).
- Mutsch M, Zhou W, Rhodes P et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N. Engl. J. Med.350, 896–903 (2004).
- Dean HJ, Chen D. Epidermal powder immunization against influenza. Vaccine23, 681–686 (2004).
- Enami M, Luytjes W, Krystal M, Palese P. Introduction of site-specific mutations into the genome of influenza virus. Proc. Natl Acad. Sci. USA87, 3802–3805 (1990).
- Hoffmann E, Krauss S, Perez D, Webby R, Webster RG. Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine20, 3165–3170 (2002).
- Hoffmann E, Mahmood K, Yang CF, Webster RG, Greenberg HB, Kemble G. Rescue of influenza B virus from eight plasmids. Proc. Natl Acad. Sci. USA99, 11411–11416 (2002).
- Neumann G, Watanabe T, Ito H et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc. Natl Acad. Sci. USA96, 9345–9350 (1999).
- Talon J, Salvatore M, O’Neill RE et al. Influenza A and B viruses expressing altered NS1 proteins: a vaccine approach. Proc. Natl Acad. Sci. USA97, 4309–4314 (2000).
- Van Kampen KR, Shi Z, Gao P et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine23, 1029–1036 (2005).
Website
- WHO. Epidemic and Pandemic Alert and Response (EPR) www.who.int/csr/disease/avian_influenza/ country/cases_table_2007_03_12/en/ index.html